Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | FPR2 | P25090 | 8/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406676 | 1.00 | CTSS (0.45) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5406477 | 1.00 | CTSS (0.45) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5406492 | 1.00 | CTSS (0.45) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5406485 | 1.00 | CTSS (0.45) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5411531 | 0.96 | CTSS (0.46) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5411541 | 0.96 | CTSS (0.46) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL5411545 | 0.96 | CTSS (0.46) | CTSSCTSKFPR2CTSBCTSL | |
| SCHEMBL8297903 | 0.88 | FPR2 (0.45) | FPR2 | |
| SCHEMBL5403771 | 0.87 | FPR2 (0.46) | CTSSFPR2IDO1MAPK1 | |
| SCHEMBL5403766 | 0.87 | FPR2 (0.46) | CTSSFPR2IDO1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CTSS 3490/4885CTSK 4240/4885FPR2 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.